Abstract
The gastrointestinal (GI) tract is commonly affected by acute and chronic graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). For patients developing GI GVHD, nonabsorbable corticosteroids such as budesonide may be used alone to reduce the risk of systemic corticosteroid toxicities or combined with systemic steroids to enhance clinical responses and to allow more rapid tapering of systemic corticosteroid doses. This prospective crossover study was conducted to evaluate what effect two commonly used antifungal agents, fluconazole, and voriconazole, would have on the trough (Cmin) and peak (Cmax) levels of budesonide in adult patients who had undergone allo-HSCT who subsequently developed clinical GI GVHD. Fifteen subjects were enrolled and nine completed the study and were evaluable. When coadministered with budesonide, voriconazole significantly increased the geometric mean of budesonide Cmin and Cmax levels by 8.52- and 6.63-fold, respectively. The cohort to evaluate the interaction with fluconazole did not meet accrual goals to reach definitive conclusions. In conclusion, this prospective study demonstrated that when patients with GI GVHD are treated with budesonide concurrently with voriconazole, the systemic concentrations of budesonide increase substantially which could increase the risk of steroid-associated toxicities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article.
References
Ibrahim RB, Abidi MH, Cronin SM, Lum LG, Al-Kadhimi Z, Ratanatharathorn V, et al. Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:395–405.
Baeher PH, Levine DS, Bouvier ME, Hockenbery DM, Gooley TA, Stern JG, et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation. 1995;60:1231–8.
McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998;115:28–35.
Iyer RV, Hahn T, Roy HN, Battiwalla M, Cooper M, Anderson B, et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transpl. 2005;11:587–92.
Castilla C, Perez-Simon A, Sanchez-Guijo M, Diez-Campelo M, Ocio E, Perez-Persona O, et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transpl. 2006;12:936–41.
Miura Y, Narimatsu H, Kami M, Kusumi E, Matsumura T, Yuji K, et al. Oral beclomethasone dipropionate as an initial treatment of gastrointestinal acute graft-versus-host disease after reduced-intensity cord blood transplantation (letter). Bone Marrow Transpl. 2006;38:577–9.
Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening FG, Rowley SD, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109:4557–63.
Villanueva FN, Perez-Simon JA, Silva FF, Caballero-Velazquez TT, Sanchez-Guijo FF, Canizo CC, et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:1331–6.
Andree H, Hilgendorf I, Leithaueuser M, Junghanss C, Holzhueter S, Loddenkemper C, et al. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. Bone Marrow Transpl. 2008;42:541–6.
Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transpl. 1999;24:1185–9.
Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1994;23:137–42.
Product information. Entocort EC (budesonide). Wilmington, DE: AstraZeneca; 2011.
Ufer M, Dilger K, Leschhorn L, Daufresne LM, Mosyagin I, Rosenstiel P, et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther. 2008;84:43–6.
Seidegard J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin Pharmacol Ther. 2000;68:13–17.
El Fakih R, Obi GA, Scholoff A, Carrum G, Kamble RT. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles (letter). Bone Marrow Transpl. 2012;47:1370–1.
Jones W, Chastain CA, Wright PW. Iatrogenic Cushing syndrome secondary to a probable interaction between voriconazole and budesonide. Pharmacotherapy. 2014;34:e116–9. https://doi.org/10.1002/phar.1432.
Frankel JK, Packer CD. Cushing’s syndrome due to antiretroviral-budesonide interaction (letter). Ann Pharmacother. 2011;45:823–4.
Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing’s syndrome secondary to ritonavir and budesonide (letter). S Afr Med J. 2010;100:296–7.
Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing’s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010;47:830–1.
Yoganathan K, David L, Williams C, Jones K. Cushing’s syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. Int J STD AIDS. 2012;23:520–1.
Colpitts L, Murray TB, Tahhan SG, Boggs JP. Iatrogenic Cushing syndrome in a 47-year-old HIV-positive woman on ritonavir and inhaled budesonide. J Int Assoc Provid AIDS Care. 2017;16:531–4.
Veilleux O, Lee TC, McDonald EG. Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide. CMAJ. 2017;189:E1188–91. https://doi.org/10.1503/cmaj.170415.
Blondin MC, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocr Pract. 2013;19:e138–41.
De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing’s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros. 2003;2:72–5.
Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing’s Syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother. 2004;38:46–9.
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrobial Chemother. 2014;69:1162–76.
Chau MM, Kong DCM, van Hal SJ, Urbancic K, Trubiano JA, Cassumbhoy M, et al. Consensus guidelines for optimizing antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014;44:1364–88.
Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing’s syndrome. Ann Int Med. 1984;101:334–8.
Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000;85:42–7.
Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol. 1989;84:688–700.
Acknowledgements
The authors gratefully acknowledge the contributions of Juan Gea-Banacloche, MD for his assistance in the initial design of the protocol, Jaydira Del Rivero, MD for her assistance in the review of the final paper, and to all the research subjects who participated in the trial. This research was supported [in part] by the Intramural Research Program of the NIH, National Heart, Lung, and Blood Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hughes, T.E., Stansfield, L., Kumar, P. et al. A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. Bone Marrow Transplant 55, 1085–1092 (2020). https://doi.org/10.1038/s41409-020-0786-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0786-8
This article is cited by
-
Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review
International Journal of Hematology (2023)